Biopharmaceutical company Modis Therapeutics revealed on Tuesday the receipt of European Medicines Agency (EMA) PRIME (PRIority MEdicines) designation for its investigational MT1621 for patients with thymidine kinase 2 deficiency (TK2d).
Thymidine kinase 2 deficiency (TK2d) is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. TK2d may present at all ages and causes progressive and severe muscle weakness, respiratory insufficiency and is often fatal.
The company added that MT1621 is an investigational deoxynucleoside combination therapy that targets the underlying pathophysiology of TK2 deficiency. Deoxynucleoside combination therapy has been shown to improve cell function and prolong life in preclinical models of TK2d.
According to the company, the application was supported by data from initial clinical studies in TK2d patients, some of which was presented by Dr Michio Hirano at the International World Muscle Society (WMS) Congress last month. The data from the initial clinical studies suggest that this therapy may alter the course of disease in patients with TK2d. It is planning to conduct additional clinical studies with the goal of obtaining regulatory approval to make MT1621 available to patients globally.
Through PRIME, the EMA offers enhanced support to medicine developers including early interaction and dialogue and a pathway for accelerated evaluation by the agency. It is intended to optimize development plans and expedite the review and approval process so that these medicines may reach patients as early as possible.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review